RXL-31 50mg | Research Peptide | 99%+ Purity | CAS 736992-21-5 | RemedyX Labs
RXL-31 50mg — high-purity research peptide with independently verified 99%+ purity and a batch-specific Certificate of Analysis (COA) CAS 736992-21-5. Available for in-vitro research use from RemedyX Labs. Third-party tested, research use only.
RXL-31 (SS-31) is a synthetic, mitochondria-targeted tetrapeptide studied for its ability to concentrate at the inner mitochondrial membrane and reduce oxidative damage. Research applications include models of mitochondrial dysfunction, cardiac and renal ischemia-reperfusion injury, and age-related cellular energy decline. Every batch is independently tested by a third-party laboratory to confirm identity and purity, with batch-specific Certificates of Analysis (COA) available for full transparency. For laboratory research use only. Not for human or animal use. Not intended for diagnostic, therapeutic, clinical, or commercial use.
- Price: 149.00 USD
- In stock
- Purity: 99%+
- CAS Number: 736992-21-5
- Molecular Formula: C32H49N9O5
- Molecular Weight: 639.8
- SKU: RXL-SKU-0050
Cited Research
The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action
Using NMR and molecular dynamics, researchers showed SS-31 selectively inserts into cardiolipin-rich lipid bilayers and reduces negative surface electrostatics at the inner mitochondrial membrane.
Journal of Biological Chemistry, 2020
The Mitochondrial-Targeted Compound SS-31 Re-Energizes Ischemic Mitochondria by Interacting with Cardiolipin
SS-31 restored cytochrome c–cardiolipin binding after ischemia, accelerating ATP recovery and reducing renal tubular injury in a rat acute kidney injury model.
Journal of the American Society of Nephrology, 2013
The cardiolipin-binding peptide elamipretide mitigates fragmentation of cristae networks following cardiac ischemia reperfusion in rats
3D electron microscopy revealed that elamipretide preserved continuous cristae network architecture and improved mitochondrial respiration in rat hearts subjected to ischemia-reperfusion.
Communications Biology, 2020
Mitochondrial protein interaction landscape of SS-31
Cross-linking mass spectrometry mapped SS-31's physical interaction partners in aged cardiac mitochondria, identifying ETC complexes and the adenine nucleotide translocator as principal binding sites.
Proceedings of the National Academy of Sciences, 2020
Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice
A single dose of SS-31 rapidly restored mitochondrial respiration and reduced ROS in aged mouse skeletal muscle, improving in vivo exercise capacity within 24 hours.
Aging Cell, 2013
Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice
Eight weeks of SS-31 treatment in aged mice reduced mitochondrial ROS emission and oxidized glutathione levels, correlating with significant improvements in treadmill performance and grip strength.
Free Radical Biology and Medicine, 2019
In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial
A randomized crossover trial used ³¹P-MRS to show a single elamipretide injection significantly increased mitochondrial ATP synthesis rates in older adult skeletal muscle versus placebo.
PLOS ONE, 2021
Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure
Three months of daily elamipretide in a canine heart failure model improved left ventricular ejection fraction and restored mitochondrial respiratory complex activity in myocardial biopsies.
Circulation: Heart Failure, 2016
A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism
A randomized crossover trial in Barth syndrome patients found elamipretide treatment was associated with improvements in walk-test performance and reductions in a disease-specific cardiolipin metabolic biomarker.
Genetics in Medicine, 2021
Restoring mitochondrial superoxide levels with elamipretide (MTP-131) protects db/db mice against progression of diabetic kidney disease
Elamipretide normalized suppressed mitochondrial superoxide in diabetic mouse kidneys, reducing albuminuria and glomerular injury in a type 2 diabetes nephropathy model.
Journal of Biological Chemistry, 2020
The mitochondrially targeted peptide elamipretide improves mitochondrial ADP sensitivity in aging
Reports improved adenine-nucleotide-translocator function and mitochondrial sensitivity in aging models.
PubMed, 2023
Application research of novel peptide mitochondrial-targeted antioxidant SS-31
Reviews broad preclinical therapeutic applications and emerging clinical research.
PubMed, 2024
Elamipretide improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide
Reports improved mitochondrial and behavioral measures in an inflammatory mouse model.
PubMed, 2019
Elamipretide: A Review of Its Structure, Mechanism of Action and Therapeutic Potential
Reviews cardiolipin binding, mitochondrial effects and clinical-development programs.
PubMed, 2025
SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease
Reviews renal protective mechanisms and experimental studies.
PMC, 2022
Mitochondrial protein interaction landscape of SS-31
Maps mitochondrial protein interactions that may explain SS-31 pharmacology.
PubMed, 2020
Elamipretide treatment attenuates age-associated retinal and visual dysfunction
Reports improvement in selected age-associated ocular endpoints.
PubMed, 2021
The effects of elamipretide on mitochondrial function in aged skeletal muscle
Examines mitochondrial and functional responses in aging muscle.
PMC, 2021
Evaluation of SS-31 as a Potential Strategy for Mitochondrial Dysfunction
Reviews disease models and early clinical-trial experience.
PubMed, 2022